An OpenAI researcher is leaving to build a $2bn AI drug startup that has no name yet

No name. No product. No confirmed funding. And, possibly, a $2bn price tag. That is the shape of the newest bet in AI drug discovery. Miles Wang, a researcher at OpenAI, is leaving to start his own company, TechCrunch reported. He is in talks to raise about $200m at a $2bn valuation, with Lightspeed in […] This story continues at The Next Web